tbuckley/cabot-search huggingface dataset:
The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression
Authors: Michel Delforge, Philippe Moreau, Maria-Victoria Mateos, Valerio De Stefano, Katja Weisel, Jesús San-Miguel, Hermann Einsele, Thierry Facon, Mario Boccadoro, Hartmut Goldschmidt, Michele Cavo, Laura Rosinol, Martin F. Kaiser, Francesca Gay, Christof Scheid, Annemiek Broyl, Niels W. C. J. Van De Donk, Paula Rodriguez, Anna Potamianou, Caline Sakabedoyan, Vadim Strulev, Tonia Nesheiwat, Paul Bergmans, Syed Rizvi, Arkadiusz Pilatowicz, Pieter Sonneveld
Journal: Blood (2019)
2'-O-Methoxyethyl Splice-Switching Oligos to Reverse Splicing from IVS2-745 β-Thalassemia Patient Cells: A Foundation for Potential Therapies
Authors: Valentina Ghiaccio, Alisa Dong, Irene Motta, Shuling Guo, Raechel Peralta, Susan M Freier, Andy Watt, Yasuhiro Ikawa, Maxwell Chappell, Coralea Stephanou, Paola Delbini, Connie Chen, Soteroula Christou, Marina Kleanthous, Kim Smith-Whitley, Deepa Manwani, Carla Casu, Maria Domenica Cappellini, Osheiza Abdulmalik, Stefano Rivella, Laura Breda
Journal: Blood (2019)
TAZ Is a Negative Regulator of PPARγ Activity in Adipocytes and TAZ Deletion Improves Insulin Sensitivity and Glucose Tolerance
Authors: Dalila El Ouarrat, Roi Isaac, Yun Sok Lee, Da Young Oh, Joshua Wollam, Denise Lackey, Matthew Riopel, Gautam Bandyopadhyay, Jong Bae Seo, Revathy Sampath-Kumar, Jerrold M. Olefsky
Journal: Cell Metabolism (2019)
Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure
Authors: Domenico Luca Grieco, Luca S. Menga, Valeria Raggi, Filippo Bongiovanni, Gian Marco Anzellotti, Eloisa S. Tanzarella, Maria Grazia Bocci, Giovanna Mercurio, Antonio M. Dell’Anna, Davide Eleuteri, Giuseppe Bello, Riccardo Maviglia, Giorgio Conti, Salvatore Maurizio Maggiore, Massimo Antonelli
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Rationale: High-flow nasal cannula (HFNC) and helmet noninvasive ventilation (NIV) are used for the management of acute hypoxemic respiratory failure.Objectives: Physiological comparison of HFNC and helmet NIV in patients with hypoxemia.Methods: Fifteen patients with hypoxemia with PaO2/FiO2 < 200 mm Hg received helmet NIV (positive end-expiratory pressure ≥ 10 cm H2O, pressure support = 10-15 cm H2O) and HFNC (50 L/min) in randomized crossover order. Arterial blood gases, dyspnea, and comfort were recorded. Inspiratory effort was estimated by esophageal pressure (Pes) swings. Pes-simplified pressure-time product and transpulmonary pressure swings were measured.Measurements and Main Results: As compared with HFNC, helmet NIV increased PaO2/FiO2 (median [interquartile range]: 255 mm Hg [140-299] vs. 138 [101-172]; P = 0.001) and lowered inspiratory effort (7 cm H2O [4-11] vs. 15 [8-19]; P = 0.001) in all patients. Inspiratory effort reduction by NIV was linearly related to inspiratory effort during HFNC (r = 0.84; P < 0.001). Helmet NIV reduced respiratory rate (24 breaths/min [23-31] vs. 29 [26-32]; P = 0.027), Pes-simplified pressure-time product (93 cm H2O ⋅ s ⋅ min-1 [43-138] vs. 200 [168-335]; P = 0.001), and dyspnea (visual analog scale 3 [2-5] vs. 8 [6-9]; P = 0.002), without affecting PaCO2 (P = 0.80) and comfort (P = 0.50). In the overall cohort, transpulmonary pressure swings were not different between treatments (NIV = 18 cm H2O [14-21] vs. HFNC = 15 [8-19]; P = 0.11), but patients exhibiting lower inspiratory effort on HFNC experienced increases in transpulmonary pressure swings with helmet NIV. Higher transpulmonary pressure swings during NIV were associated with subsequent need for intubation.Conclusions: As compared with HFNC in hypoxemic respiratory failure, helmet NIV improves oxygenation, reduces dyspnea, inspiratory effort, and simplified pressure-time product, with similar transpulmonary pressure swings, PaCO2, and comfort.
SURG-04. INTRAOPERATIVE HAND-HELD LINE-SCANNED DUAL-AXIS CONFOCAL MICROSCOPY FOR VISUALIZING LOW-GRADE GLIOMAS
Authors: Yoko Fujita, Linpeng Wei, Jonathan T C Liu, Nader Sanai
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Extent of resection is a prognostic factor for low- and high-grade gliomas. Fluorescence guided surgery (FGS) using five-aminolevulinic acid (5-ALA) is associated with greater extent of resection in high-grade gliomas. However, for low-grade gliomas, intraoperative imaging technologies such as FGS, have not been optimized to distinguish tumor from normal tissue. Intraoperative confocal microscopy can better visualize tissue cytoarchitecture in real-time. Here we report on the feasibility of a newly-developed, hand-held, line-scanned dual-axis (LS-DAC) confocal microscope in distinguishing tumor vs. normal cells in ex vivo human low-grade glioma tissue. METHOD Ten low-grade glioma patients who underwent craniotomy were enrolled. Resected specimens were labelled with acridine orange (1mM) for one minute, and exposed surfaces were immediately imaged by our device. Subsequently, specimens were cut into sections and stained with H&amp;E for histopathological analysis. RESULTS LS-DAC confocal microscope visualized nuclei of tumor cells vs. surrounding tissue, demonstrating clear differences in cellularity in the two compartments. Acquired images were comparable to those observed on matched H&amp;E-stained sections. Live images provided minimal motion artifact due to the higher frame rate of 16 Hz. CONCLUSION LS-DAC confocal microscope provided real-time, high-contrast mosaic images of human low-grade glioma tissue ex vivo. The ability to distinguish tumor vs. normal tissue at the cellular level with little motion artifact, as well as the device’s hand-held design, suggests this technology merits additional investigation as an intraoperative adjunct for low-grade glioma surgery.
Community-driven development of a modified progression-free survival ratio for precision oncology trials
Authors: A. Mock, C.E. Heilig, S. Kreutzfeldt, D. Hübschmann, C. Heining, E. Schröck, B. Brors, A. Stenzinger, D. Jäger, R.F. Schlenk, H. Glimm, S. Fröhling, P. Horak
Journal: Annals of Oncology (2019)
Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects
Authors: Yan Chen, Chen Chen, Xiaojuan Zhang, Chuanchuan He, Pengxuan Zhao, Minsi Li, Ting Fan, Ruicong Yan, Yao Lu, Robert J. Lee, Muhammad Waseem Khan, Muhammad Sarfraz, Xiang Ma, Tan Yang, Guangya Xiang
Journal: Acta Pharmaceutica Sinica B (2019)

Platinum-based chemotherapy is used for non-small cell lung cancer (NSCLC). However, it has side effects and minimum efficacy against lung cancer metastasis. In this study, platinum-curcumin complexes were loaded into pH and redox dual-responsive nanoparticles (denoted as Pt-CUR@PSPPN) to facilitate intracellular release and synergistic anti-cancer effects. Pt-CUR@PSPPN was prepared by a nano-precipitation method and had a diameter of ∼100 nm. The nanoparticles showed increased anti-cancer effects both in vivo and in vitro. In addition, Pt-CUR@PSPPN blocked PI3K/AKT signal transduction pathway and inhibited MMP2 and VEGFR2, resulting in enhanced anti-metastatic activity. Furthermore, reduced side effects were also observed. In conclusion, Pt-CUR@PSPPN provided a novel and attractive therapeutic strategy for NSCLC.
A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy
Authors: J Christine Ye, Philip S Boonstra, Daniel F. Boyer, Larry D. Anderson, Brea C. Lipe, Andrew Kin, Erica L. Campagnaro, Matthew J. Pianko, Moshe Talpaz
Journal: Blood (2019)
Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)
Authors: Hisham Abdel-Azim, Christopher C. Dvorak, Nancy Bunin, Mark C. Walters, Julie-An Talano, Eric Jon Anderson, Jemily Malvar, May Al Jassani, Sonali Chaudhury, Mitchell S Cairo, Carrie Kitko, Allison P. Jacob, Dimitri S. Monos, Leung Wing, Michael A. Pulsipher
Journal: Blood (2019)
Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
Authors: Yinghuan Li, Xi Tan, Xuhan Liu, Lingyan Liu, Yan Fang, Rong Rao, Yuanyuan Ren, Xiangliang Yang, Wei Liu
Journal: Asian Journal of Pharmaceutical Sciences (2019)

Multiple drug resistance (MDR) is a tough problem in developing hepatocellular carcinoma (HCC) therapy. Here, we developed TPGS-coated cationic liposomes with Bcl-2 siRNA corona to load doxorubicin (Dox) i.e., Bcl-2 siRNA/Dox-TPGS-LPs, to enhance anticancer effect of Dox in HCC-MDR. TPGS i.e., d-α-tocopheryl polyethylene glycol 1000 succinate, inhibited P-glycoprotein (P-gp) efflux pump and Bcl-2 siRNA suppressed anti-apoptotic Bcl-2 protein. The Bcl-2 siRNA loaded in the liposomal corona was observed under transmission electron microscopy. The stability and hemolysis evaluation demonstrated Bcl-2 siRNA/Dox-TPGS-LPs had good biocompatibility and siRNA-corona could protect the liposomal core to avoid the attachment of fetal bovine serum. In drug-resistant cells, TPGS effectively prolonged intracellular Dox retention time and siRNA-corona did improve the internalization of Dox from liposomes. In vitro and in vivo anticancer effect of this dual-functional nanostructure was examined in HCC-MDR Bel7402/5-FU tumor model. MTT assay confirmed the IC50 value of Dox was 20-50 fold higher in Bel7402/5-FU MDR cells than that in sensitive Bel7402 cells. Bcl-2 siRNA corona successfully entered the cytosol of Bel7402/5-FU MDR cells to downregulate Bcl-2 protein levels in vitro and in vivo. Bcl-2 siRNA/Dox-TPGS-LPs showed superior to TPGS- (or siRNA-) linked Dox liposomes in cell apoptosis and cytotoxicity assay in Bel7402/5-FU MDR cells, and 7-fold greater effect than free Dox in tumor growth inhibition of Bel7402/5-FU xenograft nude mice. In conclusion, TPGS-coated cationic liposomes with Bcl-2 siRNA corona had the capacity to inhibit MDR dual-pathways and subsequently improved the anti-tumor activity of the chemotherapeutic agent co-delivered to a level that cannot be achieved by inhibiting a MDR single way.
Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium
Authors: Joanna S. Yi, Tiffany Chambers, Kelly D Getz, Tamara P. Miller, Evanette Burrows, Marla Daves, Philip J. Lupo, Michael E. Scheurer, Richard Aplenc, Karen R. Rabin, Maria Monica J. Gramatges
Journal: Blood (2019)
Malaria strains resistant to 4-amino-quinoline drugs.
Authors: P. Papworth
Journal: BMJ (1965)

MEDICALJOURNAMincontinence, or behaviour disorder with restless wandering.The last factor is the most common reason for the services of a mental hospital rather than a geriatric unit or residential home.This last group may well require some special provision since the patients are often physically and socially preserved and do not really require full hospital services, apart from their tendency for " restless wandering."Like Dr. Parnell, I see objections to the term dementia, both senile and arteriopathic, if used for potentially reversible syndromes.Other popular terms-confusional states, symptomatic psychosis, and acute organic reaction-can also be used in an imprecise way.Frequently further investigation, treatment, or time alone permit
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein
Authors: S Dermime, F Grignani, M Clerici, C Nervi, G Sozzi, GP Talamo, E Marchesi, F Formelli, G Parmiani, PG Pelicci, C Gambacorti-Passerini
Journal: Blood (1993)
Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq
Authors: Changying Jiang, Shaojun Zhang, Yuanxin Wang, Rongjia Zhang, Yang Liu, Joseph Mitchell McIntosh, Guangchun Han, Ruiping Wang, David Santos, Maria Badillo, Angela Leeming, Zhihong Chen, Kimberly Hartig, John Bigcal, Hun Ju Lee, Raphael E Steiner, Jorge Enrique Romaguera, Preetesh Jain, Krystle Nomie, Andy Futreal, Linghua Wang, Michael L. Wang
Journal: Blood (2019)
Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation
Authors: Takashi Toya, Ayumi Taguchi, Kazutaka Kitaura, Yuki Otsuka, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, Yuya Kishida, Tatsuya Konishi, Akihito Nagata, Yuta Yamada, Atsushi Marumo, Yuma Noguchi, Kota Yoshifuji, Junichi Mukae, Kyoko Inamoto, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Kazuhiko Kakihana, Kazuteru Ohashi, Ryuji Suzuki, Noriko Doki
Journal: Blood (2019)
Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple Myeloma
Authors: Nathanael Fillmore, Sarvari Venkata Yellapragada, Cenk Yildirim, Aimaz Afrough, Adanma Anji Ayanambakkam Attanathi, Ifeorah Chizoba, Nhan Do, Mary Brophy, Nikhil C. Munshi
Journal: Blood (2019)
GENE-59. NOT ALL p53 MUTATIONS ARE CREATED EQUAL: A MURINE ASTROCYTE MODEL FOR HIGH-THROUGHPUT FUNCTIONAL ASSESSMENT OF p53 MISSENSE MUTATIONS
Authors: Nathan Rockwell, Max Staller, Maria Cannella, Barak Cohen, Joshua Rubin
Journal: Neuro-Oncology (2019)

Abstract The tumor suppressor TP53 (p53) is the most commonly mutated gene in cancer and among the most frequently mutated genes in glioblastoma (GBM). The majority of p53 mutations in GBM are missense mutations in the DNA binding domain that lead to the production of full length mutant p53 protein. In addition to the complete loss of tumor suppressor function, these mutations have gain-of-function (GOF) properties either through attenuation of wild-type function or neomorphic functions. The variability in GOF mutations results in heterogeneity in cancer phenotypes between mutants that remain poorly understood. Here, we developed a murine astrocyte model to functionally assess a library of p53 mutants in parallel. Primary astrocytes were isolated from postnatal day one pups possessing a single copy of wild-type p53 flanked by loxP sites (TRP53f/-). We then built a library of 17 individual alleles of recurring mutations in GBM with flanking loxP sites. When co-transfected into the mouse astrocytes with a plasmid expressing Cre recombinase, the endogenous WT p53 was excised and replaced with a single copy of the mutant allele. In this way, all astrocytes expressed a single copy of mutant p53 from the endogenous p53 locus. As the mutant p53 cells expanded, aliquots of cells were extracted for targeted genomic sequencing of the p53 allele. Comparing the allelic frequencies of each mutant overtime revealed a wide distribution of growth rates between mutants. To validate the screen results, wildtype astrocytes were transduced with mutant p53-IRES-eGFP retrovirus to overexpress one of three mutations with divergent growth phenotypes. As observed in the initial screen, equivalent overexpression of the different p53 mutants was sufficient to induce significant differences in growth phenotype, with astrocytes expressing the Y217C growing the fastest, R172H second, and Y202C growing the slowest. Ongoing studies are evaluating mutation-specific p53 binding partners and transcriptional outputs.
RGD-Substituted High Molecular Weight Hyper-Branched Polyglycerols (HPG) Are Effective Platelet Inhibitors.
Authors: Jerry G. Zhang, Oren Krajden, Rajesh K. Kainthan, Jayachandran N. Kizhakkedathu, Maria I.C. Gyongyossy-Issa
Journal: Blood (2007)
How much physical therapy for patients with stroke?
Authors: J Knox, P Horrocks
Journal: BMJ (1978)

<h3>Introduction</h3> Research indicates that experiencing the suicide of a relative can have a significant impact on family members9 emotional health. However, research incorporating the impact of suicide bereavement on family members9 physical health is sparse. This paper details the protocol for a mixed-methods study of suicide-bereaved family members. The study will primarily examine the physical and mental health needs of those bereaved by suicide. A secondary objective of the study is to describe the support service needs of family members bereaved by suicide. <h3>Methods and analysis</h3> A mixed-methods approach, using semistructured interviews and self-report questionnaires, will be used. Interviews will be conducted with a group of 15–20 relatives who experienced suicide bereavement. This protocol will follow the COREQ checklist criteria for the reporting of qualitative research interviews. Thematic analysis will be used to examine experiences and impact of bereavement on psychological and physical health. Self-report quantitative data on well-being will be analysed using descriptive statistics. <h3>Ethics and dissemination</h3> Ethical approval to conduct this study has been granted from the Clinical Research Ethics Committee of the Cork Teaching Hospitals. Pseudonyms will be given to participants to protect anonymity. It will be explained to participants that participation in the study is voluntary and they have to right to withdraw at any time. The findings of this research will be disseminated to regional, national and international audiences through publication in peer-reviewed international journals and presentations at scientific conferences. This research also forms part of a PhD thesis.
Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy
Authors: Naoki Takezako, Naoya Kaneko, Airi Hamano, Kenichi Ito, Naohiro Sekiguchi, Satoshi Noto, Takanori Teshima
Journal: Blood (2019)
Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications
Authors: Doyoung Kwon, Sung-Mi Kim, Maria Almira Correia
Journal: Acta Pharmaceutica Sinica B (2019)

The hepatic endoplasmic reticulum (ER)-anchored cytochromes P450 (P450s) are mixed-function oxidases engaged in the biotransformation of physiologically relevant endobiotics as well as of myriad xenobiotics of therapeutic and environmental relevance. P450 ER-content and hence function is regulated by their coordinated hemoprotein syntheses and proteolytic turnover. Such P450 proteolytic turnover occurs through a process known as ER-associated degradation (ERAD) that involves ubiquitin-dependent proteasomal degradation (UPD) and/or autophagic-lysosomal degradation (ALD). Herein, on the basis of available literature reports and our own recent findings of in vitro as well as in vivo experimental studies, we discuss the therapeutic and pathophysiological implications of altered P450 ERAD and its plausible clinical relevance. We specifically (i) describe the P450 ERAD-machinery and how it may be repurposed for the generation of antigenic P450 peptides involved in P450 autoantibody pathogenesis in drug-induced acute hypersensitivity reactions and liver injury, or viral hepatitis; (ii) discuss the relevance of accelerated or disrupted P450-ERAD to the pharmacological and/or toxicological effects of clinically relevant P450 drug substrates; and (iii) detail the pathophysiological consequences of disrupted P450 ERAD, contributing to non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) under certain synergistic cellular conditions.
TRK inhibitors in TRK fusion-positive cancers
Authors: A. Drilon
Journal: Annals of Oncology (2019)

TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted landmark, tumour-agnostic regulatory approvals for the treatment of these cancers in 2018 and 2019, respectively. Brisk and durable responses are achieved with these drugs in patients, including those with locally advanced or metastatic disease. In addition, intracranial activity has been observed with both agents in TRK fusion-positive solid tumours with brain metastases and primary brain tumours. While resistance to first-generation TRK inhibition can eventually occur, next-generation agents such as selitrectinib (BAY 2731954, LOXO-195) and repotrectinib were designed to address on-target resistance, which is mediated by emergent kinase domain mutations, such as those that result in substitutions at solvent front or gatekeeper residues. These next-generation drugs are currently available in the clinic and proof-of-concept responses have been reported. This underscores the utility of sequential TRK inhibitor use in select patients, a paradigm that parallels the use of targeted therapies in other oncogenic driver-positive cancers, such as ALK fusion-positive lung cancers. While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic. These side-effects are likely consequences of the inhibition of the TRK pathway that is involved in the development and maintenance of the nervous system.
RARE-37. TREATMENT OF H3K27M MUTANT GLIOMAS WITH PANOBINOSTAT
Authors: Samantha Balakrishnan, Ivan Carabenciov, Michael Ruff, Joon Uhm, Sani Kizilbash
Journal: Neuro-Oncology (2019)

Abstract Panobinostat (PBST) is a histone deacetylase inhibitor with biologic rationale in the treatment of gliomas harboring H3 K27M mutation. METHODS We performed a retrospective medical record review of adult patients with H3 K27M mutant diffuse midline glioma treated with PBST at Mayo Clinic (Rochester, MN). RESULTS Four patients were identified with a mean age 40 years (range 22–62 years). Tumor location was: spinal cord (thoracic n=1, cervical n=1), brainstem (n=1), and thalamus (n=1).Two patients underwent biopsy alone while two underwent a partial resection. Three patients were treated with radiation (36–54 Gy) immediately prior to PBST monotherapy, and one patient was treated with PBST monotherapy without preceding radiation. All patients were otherwise chemotherapy naïve and did not receive any concurrent chemotherapy with PBST. PBST was dosed at either 10 mg (n=1) or 20mg (n=3) administered on days 1, 3, 5, 8, 10 and 12 of 21 day cycles. The mean duration of PBST therapy was 5 months (range 2–11 months). PBST was well tolerated overall. One patient experienced an objective response per RANO criteria. Two patients continue on therapy (5 cycles, 12 cycles) with stable disease. One patient rapidly progressed after 2 cycles of PBST therapy. In contrast with the patients who derived benefit from PBST, this patient was younger (22) and had multifocal disease with leptomeningeal involvement at treatment onset. The average progression free survival post PBST initiation was 8 months. CONCLUSION This single institution case series shows promise that PBST may have therapeutic benefit in adult patients with H3 K27M mutant diffuse midline glioma.
SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models
Authors: Heekyung Chung, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, Sunil KC, Betty Tam, Gail Bucci, Josh Stewart, Timothy Phalen, Steven Cha
Journal: Blood (2019)